CPT

ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2023

Retrieved on: 
Thursday, November 9, 2023
Adjustment, TK, FDA, Genetic counseling, Nebula Genomics, Research, Sale, Genomics, Endoscopy, CDX, FDM, Food, Genetic, Heart, Therapy, Hospital Insurance and Diagnostic Services Act, COVID-19 testing, Three Months, History, Public expenditure, Omicron, Diagnosis, EBITDA, Corporation, Absorption, Genetics, Exercise, Prophase, House, Whole genome sequencing, Internet, Health Resources and Services Administration, COVID-19, Medicine, Marketing, Stella, WGS, CPT, Current Procedural Terminology, Patient, Anesthesia, Automation, Antibiotics, Renewable energy, Mobile phone, Clothing, Life insurance, Security (finance), Fine chemical, Birth control, Auction, Broadcasting, Pharmaceutical industry, Cryptocurrency, Bosc

Garden City, NY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three and nine months ended September 30, 2023.

Key Points: 
  • Three Months Ended September 30, 2023 as compared to the Three Months Ended September 30, 2022.
  • Net revenue for the three months ended September 30, 2023 was $8.4 million as compared to $24.2 million for the three months ended September 30, 2022.
  • Diagnostic services costs for the three months ended September 30, 2023 were $0.1 million compared to $2.4 million for the three months ended September 30, 2022.
  • Adjusted EBITDA loss for the three months ended September 30, 2023 was $(2.5) million compared to adjusted EBITDA income of $6.3 million for the three months ended September 30, 2023.

Monte Nido & Affiliates Expands Eating Disorder Treatment with New Location in Manhattan

Retrieved on: 
Wednesday, November 8, 2023
PHP, Briarcliff Manor, New York, Psychiatry, Prevalence, IOP, Doctor of Philosophy, Research, Trauma, PTSD, LMHC, Bryant Park, Helsinki University Central Hospital, Eating, CPT, Intensive outpatient program, Eating disorder, Nursing, Casino

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Monte Nido & Affiliates, one of the leading eating disorder treatment providers in the country, today announces the expansion and re-location of Monte Nido Manhattan Eating Disorder Day Treatment. The program, located in Midtown near Bryant Park, provides eating disorder treatment for adolescents and adults of all genders. 

Key Points: 
  • NEW YORK, Nov. 8, 2023 /PRNewswire/ -- Monte Nido & Affiliates , one of the leading eating disorder treatment providers in the country, today announces the expansion and re-location of Monte Nido Manhattan Eating Disorder Day Treatment .
  • "Monte Nido provides an individualized treatment approach to account for the unique needs of every individual," said Melissa Spann, PhD, LMHC, CEDS-C, Chief Clinical Officer of Monte Nido & Affiliates.
  • Monte Nido Manhattan is the seventh Monte Nido & Affiliates program in the state of New York, complementing the day treatment program in Westchester , and residential programs in Glen Cove , River Towns , Rockland , Briarcliff Manor and Hudson Valley .
  • For more information, or to inquire about treatment at Monte Nido Manhattan, please visit www.montenido.com or call 888-228-1253.

AAHKS Grants Force Therapeutics the 2023 Industry Innovation Award

Retrieved on: 
Wednesday, November 8, 2023
Documentation, FDA, Food, Medical device, Medicare, Data collection, MD, MSK, Health, Software, RTM, Hip, Center for Medicare and Medicaid Innovation, FRCS, CPT, Centers for Medicare & Medicaid Services, Therapy, Patient, Food and Drug Administration, Automation, Force, CMS, Pharmaceutical industry

NEW YORK, Nov. 8, 2023 /PRNewswire/ -- On Friday, November 3, Force Therapeutics was presented the Industry Innovation Award by the American Association of Hip and Knee Surgeons (AAHKS) at the AAHKS Annual Meeting in Dallas, Texas.

Key Points: 
  • NEW YORK, Nov. 8, 2023 /PRNewswire/ -- On Friday, November 3, Force Therapeutics was presented the Industry Innovation Award by the American Association of Hip and Knee Surgeons (AAHKS) at the AAHKS Annual Meeting in Dallas, Texas.
  • The Industry Innovation Award is a competitive product award for companies demonstrating cutting-edge innovation in the field of orthopedic hip and knee arthroplasty.
  • "AAHKS is truly excited to grant the Industry Innovation Award to Force Therapeutics for its addition of Remote Therapeutic Monitoring (RTM) to its digital care platform.
  • Force Therapeutics' award-winning product is the addition of RTM to the Force Therapeutics digital care platform, which satisfies U.S. Food and Drug Administration (FDA) requirements as Software as a Medical Device (SaMD).

Groundbreaking Study Indicates Virtual Reality Can Enhance Relationships Between Caregivers and Aging Population

Retrieved on: 
Wednesday, November 8, 2023
Research, Virtual reality, HTC, Ageing, Stanford University, Therapy, American Medical Association, Virtual Human Interaction Lab, National Communication Association, PALO, Social network, Environment, Growth, Caregiver, Attitude, XR, Virtual, AT, Elderly care, CPT, AI, Long Mynd, AT&T, Communication, Nursing, Residential care, Cyberpsychology, VR, Behavior, DALLAS

PALO ALTO, Calif. and DALLAS, Nov. 8, 2023 /PRNewswire/ -- Virtual Reality (VR) technology is not just for the young. It's paving the way for enhancing relationships between the aging population and their caregivers, as research from the Virtual Human Interaction Lab (VHIL) at Stanford University demonstrates. 

Key Points: 
  • PALO ALTO, Calif. and DALLAS, Nov. 8, 2023 /PRNewswire/ -- Virtual Reality (VR) technology is not just for the young.
  • It's paving the way for enhancing relationships between the aging population and their caregivers, as research from the Virtual Human Interaction Lab (VHIL) at Stanford University demonstrates.
  • The study sought to understand older adults' attitudes towards new technologies, including virtual reality, and how professional caregivers felt about facilitating VR experiences for older adults.
  • The study, the largest ever conducted on VR and older adults, was done in collaboration with Mynd, the leading provider of immersive therapeutic experiences for the aging population.

Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
FDA, Research, Growth, ASC, Axitinib, ASCRS, Food, Intraocular pressure, SOL, Medicare, Eye, Telecanthus, Abdominal ultrasonography, OHT, AMD, OAG, Overalls, CPT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Patient, OPPS, Interest, Allergic conjunctivitis, Clinical trial, Marketing, Webcast, Barings LLC, Macular degeneration, Depreciation, Safety, SPA, Visual acuity, Trial of the century, Pain, Centers for Medicare & Medicaid Services, CMS, Pharmaceutical industry, Beauty salon, Fine chemical, Medical device, Birth control, Video game

BEDFORD, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the third quarter ended September 30, 2023, and provided updates on its ophthalmology pipeline.

Key Points: 
  • “We made significant progress at Ocular Therapeutix in the third quarter,” said Antony Mattessich, President and CEO.
  • The Company also recorded gains and losses from debt extinguishment, net, of $14.2 million in the third quarter of 2023.
  • Non-cash charges for stock-based compensation and depreciation and amortization were $5.4 million in the third quarter of 2023 versus $4.7 million for the comparable quarter in 2022.
  • Members of the Ocular Therapeutix management team will host a live conference call and webcast today at 4:30 pm Eastern Time to review the Company's financial results and provide a general business update.

Valencia Technologies Corporation announced today that the Department of Health and Human Services, Centers for Medicare & Medicaid Services (CMS), published the 2024 Medicare Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment

Retrieved on: 
Tuesday, November 7, 2023
Patient, FDA, ASC, Health, Ambulatory Surgery Center Association, Medicare, OAB, The Final Rule, PMA, United, AMA, Addendum, Quality of life, Leg, APC, Physician, Safety, CPT, Outpatient surgery, Hospital, Urinary incontinence, CMS

VALENCIA, Calif., Nov. 7, 2023 /PRNewswire/ -- As outlined in the 2024 Medicare Program: HOPPS and ASC Payment Systems Final Rule, CMS has confirmed that new Category III CPT code 0816T for reporting the eCoin system implantable tibial nerve stimulation procedure across all service locations has been assigned to Medicare Hospital Outpatient Prospective Payment System Ambulatory Payment Classification (APC) 5464 beginning CY'24. In the hospital outpatient site of service, APC 5464 has been assigned a Medicare unadjusted, national average payment rate of US$20,865, as referenced in Addendums A and B of the Final Rule. 

Key Points: 
  • Furthermore, CPT code 0816T describing the eCoin system procedure has been categorized as device-intensive by CMS.
  • This categorization ensures a more comprehensive Medicare payment in the Ambulatory Surgery Center (ASC) in comparison to procedures not deemed device-intensive.
  • Ann Decker, VP of Reimbursement for Valencia Technologies, commented, "The payment Rules for Hospital outpatient (HOPPS) and Ambulatory Surgery Center (ASC) by CMS are a testament to the constructive discussions between Valencia Technologies and CMS.
  • Patients are encouraged to visit Valencia's patient website at www.eCoin.us for more information about this novel therapy for UUI.

CoinPark announced the issuance plan for CoinPark Token (CPT), Igniting a New Digital Economy Wave

Retrieved on: 
Friday, October 27, 2023
CPT, Partnership, USDT, Cryptocurrency

New York, NY, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Recently, Coinpark announced the issuance plan for CoinPark Token (CPT) worldwide, which is divided into three critical phases: the Initial Round, the Institutional Round, and the Exchange Round.

Key Points: 
  • New York, NY, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Recently, Coinpark announced the issuance plan for CoinPark Token (CPT) worldwide, which is divided into three critical phases: the Initial Round, the Institutional Round, and the Exchange Round.
  • The Initial Round serves as the starting point for CPT's development and provides an opportunity for early investors to participate.
  • By offering low-cost entry for early supporters, this phase not only expands CPT's community base but also establishes strong momentum and social foundation.
  • In the burgeoning digital economy, CPT will continue to thrive, offering more opportunities and returns for investors

HistoSonics Notches Significant Reimbursement Wins

Retrieved on: 
Monday, November 6, 2023
Radiology, Research, Insurance, Oncology, Software, Medical Devices, Hardware, Hospitals, Professional Services, Science, Technology, Clinical Trials, FDA, Biotechnology, Surgery, Health, Health Technology, Health Insurance, Liver, Sale, Medicare, Government, Diagnosis-related group, Physician, High-intensity focused ultrasound, American Medical Association, Infection, Kidney, Bleeding, Blue, Ambulatory Payment Classification, Multimedia, IDE, AMA, Tissue, APC, Diagnosis, Hospital, Centers for Medicare & Medicaid Services, CPT, Pain, Patient, Investigational New Drug, DRG, CMS, Medical imaging, Medicaid

We commend CMS on facilitating access to breakthrough devices like ours for Medicare patients, many of whom historically have had delayed access to innovative technology,” commented HistoSonics President and CEO Mike Blue.

Key Points: 
  • We commend CMS on facilitating access to breakthrough devices like ours for Medicare patients, many of whom historically have had delayed access to innovative technology,” commented HistoSonics President and CEO Mike Blue.
  • HistoSonics’ Edison Histotripsy System combines advanced imaging and proprietary software to deliver patient specific treatments and uses the science of histotripsy to mechanically destroy targeted tissues at sub-cellular levels.
  • Additionally, the American Medical Association (AMA) has recently issued a new Category III CPT code for histotripsy of kidney tissue.
  • The release of this new code represents a major reimbursement milestone as hospitals across the US will be able to submit claims directly related to the service.

Aerin Medical Announces Advances for Chronic Rhinitis Treatment with New CPT® Code and Final CMS-Established Payment Rates

Retrieved on: 
Friday, November 3, 2023
Medical Supplies, Health, Medical Devices, Health Technology, Other Health, Other Science, Science, PNN, ENT, Education, Medicare, Aerin Lauder, Ear, Physician, American Medical Association, Nose, Rhinorrhea, MBA, Radiofrequency ablation, AMA, Multimedia, Congestion, Partnership, Center for Medicare and Medicaid Innovation, Allergy, CPT, Patient, Centers for Medicare & Medicaid Services, CMS, Thomas Jefferson University, Hospital, Nursing, Health insurance

The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.

Key Points: 
  • The new code describes the procedure performed by ENT physicians when treating overactive nerves that drive chronic rhinitis symptoms with Aerin Medical’s RhinAer®.
  • View the full release here: https://www.businesswire.com/news/home/20231031993246/en/
    CMS is set to implement a new CPT code that improves access to chronic rhinitis treatment with RhinAer® for patients often stuck in an unproductive cycle of care.
  • RhinAer is supported by a strong body of clinical evidence demonstrating significant, durable symptom improvement for chronic rhinitis patients.
  • Treatment with RhinAer is non-invasive and can be performed by ENT physicians in the office and outpatient surgical settings.

QuantalX Secures Dedicated Reimbursement Code for Delphi-MD Test, Advancing Improved Brain Health

Retrieved on: 
Thursday, November 2, 2023
Stroke, FDA, MRI, Medicare, Neurology, American Medical Association, Physician, Breakthrough, Doctor of Philosophy, Health, Dementia, AMA, DSM-IV codes, Caregiver, Myenteric plexus, NPH, Risk, CT, Brain, CPT, Patient, VPS, Pharmaceutical industry, Medical imaging

NEW YORK, Nov. 2, 2023 /PRNewswire/ -- QuantalX Neuroscience, a pioneering healthcare company dedicated to early detection of brain disorders, is pleased to announce that it has secured a US reimbursement code, 0858T, from the American Medical Association (AMA). This milestone achievement is a significant part of the company's pre-commercialization strategy in the US.

Key Points: 
  • QuantalX announces the authorization of a dedicated US reimbursement code for its point-of-care brain health test by the American Medical Association (AMA).
  • NEW YORK, Nov. 2, 2023 /PRNewswire/ -- QuantalX Neuroscience , a pioneering healthcare company dedicated to early detection of brain disorders, is pleased to announce that it has secured a US reimbursement code, 0858T, from the American Medical Association (AMA).
  • The newly assigned CPT code signifies Delphi-MD's importance in early brain health assessment, catering to brain health evaluation procedures at any clinical setting using a collaborative care model.
  • The Delphi-MD technology is  a first-in-class automated, Direct Neuro-Physiological technology to detect and assess brain abnormalities, as well as predict treatment response.